NVAX Sep 2024 7.500 put
| Previous Close | 3.5200 |
| Open | 1.2100 |
| Bid | 1.1000 |
| Ask | 1.2100 |
| Strike | 7.50 |
| Expire Date | 2024-09-20 |
| Day's Range | 1.0000 - 1.3000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
- Yahoo Finance Video
Novavax shares skyrocket on $1.2 billion Sanofi vaccine deal
Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to report more on the story. The Novavax-Sanofi deal also includes co-commercialization of the COVID-19 vaccine currently on the market. Novavax will be entitled to an additional $200 million for any new vaccines involving its adjuvant. Sanofi will receive a minority stake of less than 5% in Novavax and will invest $70 million. Shares of Novavax jumped more than 120% following the news. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Melanie Riehl
- Yahoo Finance Video
Stock markets, China tariffs, Novavax and Sanofi: 3 Things
The major stock market indexes (^DJI, ^IXIC, ^GSPC) are on the road to closing out the first full trading week of May on a high note, alongside several of its European counterparts: the FTSE 100 (^FTSE), the DAX Performance Index (^GDAXI), and the CAC 40 (^FCHI). President Biden is reportedly set to announce updates on Trump-era trade tariffs on China. Novavax (NVAX) shares are skyrocketing over 110% on news of the biotech company's plans to licensing deal with Sanofi (SNY, SAN.PA) to co-commercialize its COVID-19 vaccine For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
Investor's Business DailyBiotech Rockets 125% On Sanofi Covid Vaccine Agreement
Novavax shares shot more than 125% higher Friday on news of a Covid-19 vaccine licensing agreement with Sanofi. The agreement involves co-development of Covid/flu vaccine combinations for both companies.
